Amtagvi
Payments companies reported to CMS as associated with Amtagvi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Amtagvi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Amtagvi
These are the largest totals companies reported as associated with Amtagvi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joel Neal | Stanford, CA | Medical Oncology | $24,750.00 |
| Amanda Kirane | Palo Alto, CA | Surgery | $10,812.26 |
| Genevieve Boland | Boston, MA | Surgical Oncology | $10,000.91 |
| Janice Dutcher | New York, NY | $7,875.00 | |
| Benjamin Creelan | Tampa, FL | Internal Medicine | $7,839.72 |
| David Carbone | Columbus, OH | Medical Oncology | $7,767.21 |
| Thach-Giao Truong | Cleveland, OH | Medical Oncology | $7,709.90 |
| Daniel Olson | Chicago, IL | Hematology & Oncology | $6,804.45 |
| Charlotte Ariyan | New York, NY | Surgery | $6,780.97 |
| Justin Moser | Scottsdale, AZ | Internal Medicine | $6,163.45 |
Prescribed Amtagvi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.